Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift
Portfolio Pulse from Vandana Singh
Novartis AG is considering selling parts of its radiopharmaceuticals company, Advanced Accelerator Applications, as part of a strategic shift to focus on growth-driven areas. The company recently sold a portion of its eye medicine range to Bausch + Lomb Corporation and acquired Chinook Therapeutics Inc. However, a deal for the sale of Advanced Accelerator Applications is not guaranteed.
October 03, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Novartis AG is considering selling parts of Advanced Accelerator Applications, which could potentially impact its stock price.
The potential sale of parts of Advanced Accelerator Applications could impact Novartis' stock price, depending on the financial details of the deal and how it aligns with the company's strategic shift towards growth-driven areas.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Bausch + Lomb Corporation recently acquired a portion of Novartis' eye medicine range.
The acquisition of a portion of Novartis' eye medicine range could potentially benefit Bausch + Lomb Corporation, depending on the success of the acquired products.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50